Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) ranks among the most oversold biotech stocks to invest in. On November 20, Leerink Partners upgraded Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) from Market Perform to Outperform with a $34 price target. The rating upgrade comes despite Agios’ conflicting topline data for its Phase 3 RISE UP trial assessing mitapivat in sickle cell disease (SCD). The trial reached its primary goal, with 40.6% of patients receiving mitapivat demonstrating a 1.0 g/dL or higher increa ...